J. Chen et al., Effectiveness of beta-blocker therapy after acute myocardial infarction inelderly patients with chronic obstructive pulmonary disease or asthma, J AM COL C, 37(7), 2001, pp. 1950-1956
Citations number
24
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
OBJECTIVES We evaluated the use and effectiveness of beta-blocker therapy a
fter acute myocardial infarction (AMI) for elderly patients with chronic ob
structive pulmonary disease (COPD) or asthma.
BACKGROUND Because patients with COPD and asthma have largely been excluded
from clinical trials of beta-blocker therapy for AMI, the extent to which
these patients would benefit from beta-blocker therapy after AMI is not wel
l defined.
METHODS Using data from the Cooperative Cardiovascular Project, we examined
the relationship between discharge use of beta-blockers and one-year morta
lity in patients with COPD or asthma who were not using beta-agonists, pati
ents with COPD or asthma who were concurrently using beta-agonists and pati
ents with evidence of severe disease (use of prednisone or previous hospita
lization for COPD or asthma) compared with patients without COPD or asthma.
RESULTS Of 54,962 patients without contraindications to beta-blockers, pati
ents with COPD or asthma (20%) were significantly less likely to be prescri
bed beta-blockers at discharge after AMI. After adjusting for demographic a
nd clinical factors, we found that beta-blockers were associated with lower
one-year mortality in patients with COPD or asthma who were not on beta-ag
onist therapy (relative risk [RR] = 0.85, 95% confidence interval [CI] 0.73
to 1.00), similar to patients without COPD or asthma (RR = 0.86, 95% CI 0.
81 to 0.92). A survival benefit for beta-blockers was not found among patie
nts concurrently using beta-agonists or with severe COPD or asthma.
CONCLUSIONS Beta-blocker therapy after AMI may be beneficial for CORD or as
thma patients with mild disease. A survival benefit was not found for elder
ly AMI patients with more severe pulmonary disease. (J Am Coll Cardiol 2001
;37:1950-6) (C) 2001 by the American College of Cardiology.